Age-related features of lipid and carbohydrate metabolism and hemostasis in young patients with different components of the metabolic syndrome

Objective. To study the features of the lipid and carbohydrate metabolism, hemostasis and the level of adipokines in young patients with abdominal obesity (AO) and arterial hypertension (HTN) in different age subgroups (younger and older than 35 years).

Design and methods. The study included both males and females aged 20 to 45 years (group 1 — control, group 2 — patients with isolated AO, group 3 — patients with metabolic syndrome (MS), group 4 — patients with HTN). Patients of each group were divided into 2 subgroups: patients aged 20 to 35 years and patients aged 36 to 45 years. Laboratory parameters of carbohydrate and lipid metabolism, hemostasis and levels of leptin and adiponectin were assessed.

Results. Lipid and carbohydrate metabolism parameters differed between young patients with AO and the control group. Levels of leptin and D-dimer were increased compared to the group 1. Dyslipidemia was found in patients with MS 20–45 years old, and it was characterized by increased total cholesterol, low-density lipoprotein cholesterol and triglyceride levels and decreased high-density lipoprotein cholesterol compared to the control group. Insulin and HOMAIR value were higher than in group 1. Leptin level was higher in patients with MS compared to controls, and the adiponectin level was reduced. The hemostasis in group 3 was characterized by increased concentration of fibrinogen, decreased plasminogen activity, increased concentration of soluble fibrin monomer complex, D‑dimer, plasminogen activator inhibitor type 1, as well as the activation of anticoagulant systems. HTN patients showed changes in lipid and carbohydrate metabolism compared to the control group as following: increased total cholesterol, low density lipoprotein cholesterol and glucose. The level of D‑dimer was higher compared to the group 1.

Conclusions. Serum leptin level was higher in young patients with AO compared to patients without MS. Patients with MS aged 20–35 years showed insulin resistance. The levels of total cholesterol, low density lipoprotein cholesterol, triglycerides and leptin were comparable in young patients older the 35 with HTN and with MS. Young patients with isolated AO and isolated HTN demonstrated the activation of coagulation and fibrinolytic systems, and patients with MS showed the activation of coagulation, fibrinolytic and anticoagulant systems. Patients aged 36–45 years with MS have increased concentration of fibrinogen and decreased plasminogen activity compared to patients younger than 35 years.

1. Титов В.Н. Становление в филогенезе биологической функции эндоэкологии. Поддержание «чистоты» межклеточной среды в паракринных сообществах клеток, органах и в организме (лекция). Клиническая лабораторная диагностика. 2014;59(10):27–39. [Titov VN. The becoming of biological function of endoecology in phylogenesis. The support of “purity” of inter-cellular medium in paracrin cenosises of cells, organs and organism (a lecture). Klinicheskaya Laboratornaya Diagnostika = Russian Clinical Laboratory Diagnostics. 2014;59(10):27–39. In Russian].

2. Cinti S. Transdifferentiation properties of adipocytes in the adipose organ. Am J Physiol Endocrinol Metab. 2009;297 (5):977–86. doi: 0.1152/ajpendo.00183.2009

3. Титов В. Н. Инсулин: инициирование пула инсулинзависимых клеток, направленный перенос триглицеридов и повышение кинетических параметров окисления жирных кислот (лекция). Клиническая лабораторная диагностика. 2014;59(4):27–40. [Titov VN. Insulin: initiation of pool of insulindependent cells, targeted transfer of triglycerides and increase of kinetic parameters of oxidation of fatty acids (a lecture). Klinicheskaya Laboratornaya Diagnostika = Russian Clinical Laboratory Diagnostics. 2014;59(4):27–40. In Russian].

4. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev. 2013;93(1):1–21. doi: 10.1152/physrev.00017.2012

5. Крюков Н.Н., Гинзбург М.М., Киселева Е.В. Современный взгляд на роль асептического воспаления жировой ткани в генезе ожирения и метаболического синдрома. Артериальная гипертензия. 2013;19(4):305–10. [Kryukov NN, Ginzburg MM, Kiseleva EV. Up-to-date view at the role of aseptic inflammation of adipose tissue in the genesis of obesity and metabolic syndrome. Arterial’naya Gipertenziya = Arterial Hypertension. 2013;19 (4):305–10. In Russian].

6. Бояринова М. А., Ротарь О. П., Конради А. О. Адипокины и кардиометаболический синдром. Артериальная гипертензия. 2014;20(5):422–32. [Boyarinova MA, Rotar OP, Konradi AO. Adipokines and cardiometabolic syndrome. Arterial’naya Gipertenziya = Arterial Hypertension. 2014;20(5):422–32. In Russian].

7. Плохая А.А. Современные аспекты лечения метаболического синдрома. Ожирение и метаболизм. 2011;8(3):31–7. [Plokhaya AA. Modern aspects of treatment of metabolic syndrome. Ozhirenie i Metabolizm = Obesity and Metabolism. 2011;8 (3):31–7. doi: 10.14341/2071–8713–4834. In Russian].

8. Литвинова Л.С., Кириенкова Е.В., Аксенова Н.Н., Газатова Н.Д., Затолокин П.А. Особенности клеточного иммунитета и цитокинового репертуара у пациентов с метаболическим синдромом. Бюллетень сибирской медицины. 2012; 3:53–7. [Litvinova LS, Kiriyenkova YeV, Aksyonova NN, Gazatova ND, Zatolokin PA. Features of cellular immunity and cytokine repertoire in patients with metabolic syndrome. Bjulleten’ Sibirskoj Meditsiny = Bulletin of Siberian Medicine. 2012;3:53–7. In Russian].

9. Fitzpatrick AL, Kronmal RA, Gardner JP, Psaty BM, Jenny NS, Tracy RP et al. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol. 2007;165(1):14–21. doi: 10.1093/aje/kwj346.

10. Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. Vascular fibrosisin aging and hypertension: molecular mechanisms and clinicalimplications. Can J Cardiol. 2016;32(5):659–668. doi: 10.1016/j.cjca.2016.02.070

11. Bautista-Niño PK, Portilla-Fernandez E, Vaughan DE, Jan Danser AH, Roks AJM. DNA damage: a main determinant of vascular aging. Intern J Mol Sci. 2016;17(5):748. doi: 10.3390/ijms17050748

12. Вельков В.В. Свободные жирные кислоты: новые возможности ранней диагностики инсулинорезистентности и мониторинга тяжести ишемии. Альманах клинической медицины. 2010;23:60–4. [Velkov VV. Free fatty acids: new opportunities for early diagnosis of insulin resistance and monitoring of ischemia severity. Al’manah Klinicheskoj Meditsiny = Almanac of Clinical Medicine. 2010;23:60–4. In Russian].

13. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Comprehensive Physiology. 2013;3(1):1–58. doi:10.1002/cphy.c110062

14. Строев Ю. И., Цой М. В., Чурилов Л. П., Шишкин А.М. Классические и современные представления о метаболическом синдроме. Часть 1. Критерии, эпидемиология, этиология. Вестник Санкт-Петербургского университета. Медицина. 2007;11(1):3–15. [Stroyev YuI., Tsoy MV, Churilov LP, Shishkin AN. Classic and modern concepts of the metabolic syndrome. Part 1. Criteria, epidemiology, etiology. Vestnik Sankt-Peterburgskogo Universiteta. Meditsina = Bulletin of St Petersburg University. Medicine. 2007;11(1):3–15. In Russian].

15. Lee DE, Kehlenbrink S, Lee H, Hawkins M, Yudkin JS. Getting the message across: mechanisms of physiological cross talk by adipose tissue. Am J Physiol Endocrinol Metab. 2009;296 (6):1210–29. doi: 10.1152/ajpendo.00015.2009

16. Парфенова Н. С., Танянский Д. А. Адипонектин: благоприятное воздействие на метаболические и сердечно-сосудистые нарушения. Артериальная гипертензия. 2013;19 (1):84–96. [Parfenova NS, Tanyanskiy DA. Adiponectin: beneficial effects on metabolic and cardiovascular dysfunctions. Arterial’naya Gipertenziya = Arterial Hypertension. 2013;19(1):84–96. In Russian].

17. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities — the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334(6):374–382. doi: 10.1056/NEJM199602083340607

18. Цибулькин А.П., Фарман А.Н., Меркулова Л.М. Выраженность лептинорезистентности у больных сахарным диабетом 2‑го типа. Клиническая лабораторная диагностика. 2011;56(10):41C. [Tzybulkin AP, Farman AN, Merkulova LM. The intensity of leptinresistance in patients with diabetes mellitus type 2. Klinicheskaya Laboratornaya Diagnostika = Russian Clinical Laboratory Diagnostics. 2011;56(10):41C. In Russian].

19. Finucane FM, Luan J, Wareham NJ, Sharp SJ, O’Rahilly S, Balkau B et al. Correlation of the leptin: adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia. 2009;52(11):2345–2349. doi: 10.1007/s00125–009–1508–3

20. Chou HH, Hsu LA, Wu S, Teng MS, Sun YC, Ko YL. Leptin-to-adiponectin ratio is related to low grade inflammation and insulin resistance independent of obesity in non-diabetic Taiwanese: a cross-sectional cohort study. Acta Cardiologica Sinica. 2014;30(3):204–214.

21. Hajri T, Tao H, Wattacheril J, Marks-Shulman P, Abumrad NN. Regulation of adiponectin production by insulin: interactions with tumor necrosis factor-α and interleukin‑6. Am J Physiol Endocrinol Metab. 2011;300(2):350–60. doi: 10.1152/ajpendo.00307.2010

22. Wronska A, Kmiec Z. Structural and biochemical characteristics of various white adipose tissue depots. Acta Physiologica. 2012;205(2):194–208. doi:10.1111/j.1748–1716.2012.02409

23. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N et al. Blockade of the renin-angiotensin systemincreases adiponectin concentrationsin patients with essential hypertension. Hypertension. 2003;42(1):76–81. doi:10.1161/01.hyp.0000078490.59735.6E

24. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43(6):1318–1323. doi: 10.1161/01.hyp.0000129281.03801.4b

25. Chow WS, Cheung BMY, Tso AWK, Xu A, Wat NMS, Fong CHY et al. Hypoadiponectinemia as a predictor for the development of hypertension. A 5-year prospective study. Hypertension. 2007;49(6):1455–1461. doi: 10.1161/hypertensionaha. 107.086835

26. Kim DH, Kim C, Ding EL, Townsend MK, Lipsitz LA. Adiponectin levels and the risk of hypertension a systematic review and meta-analysis. Hypertension. 2013;62(1):27–32. doi: 10.1161/hypertensionaha.113.01453

27. Красильникова Е. И., Баранова Е. И., Благосклонная Я.В., Быстрова А.А., Волкова А.Р., Чилашвили М.А. Механизмы развития артериальной гипертензии у больных метаболическим синдромом. Артериальная гипертензия. 2011;17 (5):405–414. [Krasilnikova EI, Baranova EI, Blagosklonnaya YaV, Bystrova AA, Volkova AR, Chilashvili MA. Mechanisms of arterial hypertension in metabolic syndrome. Arterial’naya Gipertenziya = Arterial Hypertension. 2011;17(5):405–414. In Russian].

28. Титов В.Н. Адипонектин — гуморальный медиатор обратной связи в адипоцитах подкожной жировой ткани. Филогенетическая теория общей патологии; функциональное различие лептина и адипонектина. Клиническая лабораторная диагностика. 2015;60(7):4–14. [Titov VN. Adiponertin as humoral mediator of feedback in adipocytes of subcutaneous fatty tissue. Phylogenetic theory of general pathology; functional difference of leptin and adiponertin. Klinicheskaya Laboratornaya Diagnostika = Russian Clinical Laboratory Diagnostics. 2015;60(7):4–14. In Russian].